DPP4-Inhibitors and Bone Metabolism in Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

Also called NCT06770894

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 132 participants (enrolled count) (from the registry)
Sponsor
Azienda Policlinico Umberto I (from the registry)
Registry
  • NCT NCT06770894
  • EudraCT 2018-000859-40
Other papers using this trial's data
  • Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial BMC medicine, 2025-10-14 DOI, PubMed 41088165, PMC12522551 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06770894. Randomized; triple masking; primary purpose treatment. Start 2019-09-24 (actual); primary completion 2023-10-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DPP4-Inhibitors and Bone Metabolism in Diabetes
Acronym
SlowDOWN
Condition
Osteoporosis
Condition
Bone Loss, Postmenopausal
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
Sitagliptin 100 mg
Intervention (Drug)
Placebo Tablets
Lead sponsor
Azienda Policlinico Umberto I (class: other)
Collaborator
Agenzia Italiana del Farmaco (class: other government)

Record details

Record id
cardio:ct-nct06770894
Content hash
ef159945db8d7a07a492252aa7f0d2e0a597928c560524f357079f3cdaaec74d